Yocum v. United States

66 Fed. Cl. 579, 36 Employee Benefits Cas. (BNA) 1385, 96 A.F.T.R.2d (RIA) 5030, 2005 U.S. Claims LEXIS 183, 2005 WL 1592952
CourtUnited States Court of Federal Claims
DecidedJuly 1, 2005
DocketNo. 03-84 T
StatusPublished
Cited by3 cases

This text of 66 Fed. Cl. 579 (Yocum v. United States) is published on Counsel Stack Legal Research, covering United States Court of Federal Claims primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Yocum v. United States, 66 Fed. Cl. 579, 36 Employee Benefits Cas. (BNA) 1385, 96 A.F.T.R.2d (RIA) 5030, 2005 U.S. Claims LEXIS 183, 2005 WL 1592952 (uscfc 2005).

Opinion

OPINION

ALLEGRA, Judge.

It is chronicled that Thomas Scott Baldwin, the inventor of the modem parachute, helped finance his other inventions, including improvements in the dirigible, by offering to parachute to the ground from a balloon, at the rate of a dollar per foot of descent. A star attraction at many fairs, Captain Baldwin, on January 30, 1885, made one of his most famous and lucrative jumps, receiving the unheard of sum of $1000 to parachute into San Francisco’s Golden Gate Park. This tax refund case involves a “golden parachute” of a different sort, albeit one that, like Baldwin’s, showered benefits upon its owner. In the case sub judice, a corporate executive received those benefits, per agreement, in [580]*580the form of previously-issued stock that became vested and unrestricted when his company transferred a significant portion of its assets to a joint venture. At issue is the tax treatment of this transaction and, specifically, whether the subject transfer of assets triggered an “excess parachute payment” subject to the excise tax imposed by section 4999 of the Internal Revenue Code of 1986 (26 U.S.C.) (hereinafter “the Code”).

I. Fact Summary

The facts in this case are largely stipulated and, insofar as relevant, are as follows:

In 1989, Dr. Ronald H. Yocum (“Dr. Yo-cum”) began working for Quantum Chemical Corporation, and, in 1993, was named its president and chief executive officer. On October 1, 1996, Quantum became a subsidiary of Millennium Chemical, Inc. (“Millennium”). A week later, on October 8, 1996, Millennium and Dr. Yocum entered into a Restricted Stock Agreement (“the restricted stock agreement”). Pursuant to that agreement, Dr. Yocum received 224,026 shares of common stock of Millennium that were subject to restrictions and a vesting schedule. By check dated December 15, 1996, Dr. Yo-cum paid $.01 for each share of the restricted stock, for a total of $2,240.26. The restricted stock agreement prohibited Dr. Yocum from selling, transferring, pledging, hypothecating, assigning or otherwise disposing of the restricted stock, except as set forth in the Millennium Long Term Stock Incentive Plan or the agreement. Under an acceleration clause, as long as Dr. Yocum was employed by Millennium or a subsidiary of Millennium, upon a “change in control” all unvested shares of the restricted stock, whether or not earned, would become immediately vested and cease to be restricted. The restricted stock agreement defined “change of control,” as “either a Change in Control of the Company or a Change in Control of the Employer,” and provided detailed definitions of both. Dr. Yocum did not include the value of the stock in his 1996 taxable income because it was subject to restrictions on transferability and substantial risks of forfeiture within the meaning of section 83 of the Code.

On March 3, 1997, Quantum became Millennium Petrochemicals Inc. (“MPI”), which was a wholly-owned fifth tier subsidiary of Millennium. Plaintiff retained his position as president and chief executive officer.

In January of 1997, the senior management of Millennium and Lyondell Petrochemical Company (“Lyondell”) began to explore combining their ethylene and polyethylene businesses. These negotiations progressed to a point that, in February of 1997, the companies executed a confidentiality and standstill agreement. By the middle of June of that year, the companies decided to form a joint venture, and reached a preliminary agreement on their respective contributions and relative ownership percentages. On July 25, 1997, they executed a master transaction agreement, which was amended on October 10, 1997. The agreement provided that, in exchange for a contribution of $570,000, Lyondell would receive a 57 percent interest in the partnership, while for $430,000, Millennium would receive a 43 percent interest therein.

On October 17, 1997, Millennium and Lyondell filed a joint proxy statement with the Securities and Exchange Commission, which detailed the proposed formation of the proposed joint venture, Equistar Chemicals, L.P. (“Equistar”). While noting that the board of directors of both companies had unanimously approved the deal, the proxy stated that the joint venture would not become effective until a majority of both company’s shareholders had approved the deal. Upon that approval, MPI was to contribute to Equistar substantially all of its assets comprising its polyethylene and related products businesses, thereby triggering a series of other arrangements made between the companies. Regarding control of Equistar, the proxy statement revealed that “Lyondell and Millennium will have an equal voice in the most important joint venture decisions,” such as changes in basic scope of business, merging or combining with another business, and issuing or repurchasing equity securities of the Equistar. However, the joint venture agreement provided that lesser decisions could be made by Lyondell’s representatives alone. Among these was the selection of the [581]*581Equistar’s chief executive officer (“CEO”), which the joint venture agreement stated would be Lyondell’s current CEO, with the current vice president of MPI becoming the president and chief operating officer of Equistar.

As described in the proxy statement, the joint venture agreement provided that the day-to-day operations of Equistar would be run by executive officers under the supervision of the Partnership Governance Committee. Although Lyondell and Millennium were to have an equal number of representatives on that committee, Lyondell was to exercise greater control—

In general, the approval of two or more Representatives acting for Lyondell GP will be necessary and sufficient for the Partnership Governance Committee to take any action; however, the Partnership Governance Committee may not take certain actions unless they are approved by two Representatives of Lyondell GP and two Representatives of Millennium GP, as described below____This means, in effect, that Lyondell’s Representatives will control the Partnership Governance Committee (and, as a result, the Partnership) except where the approval of Millennium’s Representatives is required.

The proxy statement explained that the ownership split was decided after evaluating the contributions and debts that each company brought to Equistar.

On December 1, 1997, Millennium and Lyondell completed the joint venture to form Equistar. On that date, a group of nine institutional investors that owned shares in Millennium also owned at least 18.29 percent of the total outstanding shares of Lyondell— hereinafter, these shareholders will be referred to as the “overlapping shareholders.”1 At some point after December 1, 1997, Millennium determined that MPI’s contribution of assets to Equistar was a “change in control,” as defined in its restricted stock agreement with Dr. Yocum. It, therefore, treated the stock as vesting on that date, no longer subject to restrictions on transferability or substantial risks of forfeiture. As a result, Dr. Yocum was deemed to have realized taxable compensation income. Millennium treated this compensation as an “excess parachute payment,” within the meaning of section 280G(b)(l) of the Code, setting the amount of such excess at $5,733,409. Pursuant to section 4999 of the Code, Millennium withheld $1,146,682 from Dr. Yocum’s 1997 wages as an excise tax on the excess parachute payment and paid over such amount to the Internal Revenue Service (“IRS”), along with other employment taxes on Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Callum v. CVS Health Corp.
137 F. Supp. 3d 817 (D. South Carolina, 2015)
Moore's Cafeteria Services v. United States
77 Fed. Cl. 180 (Federal Claims, 2007)
Grapevine Imports, Ltd. v. United States
71 Fed. Cl. 324 (Federal Claims, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
66 Fed. Cl. 579, 36 Employee Benefits Cas. (BNA) 1385, 96 A.F.T.R.2d (RIA) 5030, 2005 U.S. Claims LEXIS 183, 2005 WL 1592952, Counsel Stack Legal Research, https://law.counselstack.com/opinion/yocum-v-united-states-uscfc-2005.